IS5233A - Greining á fjölgenesamsætum tengdum umbunarskortsheilkenni (reward deficiency syndrome) og efnablöndum til meðferðar við því - Google Patents

Greining á fjölgenesamsætum tengdum umbunarskortsheilkenni (reward deficiency syndrome) og efnablöndum til meðferðar við því

Info

Publication number
IS5233A
IS5233A IS5233A IS5233A IS5233A IS 5233 A IS5233 A IS 5233A IS 5233 A IS5233 A IS 5233A IS 5233 A IS5233 A IS 5233A IS 5233 A IS5233 A IS 5233A
Authority
IS
Iceland
Prior art keywords
preparations
diagnosis
deficiency syndrome
reward deficiency
reward
Prior art date
Application number
IS5233A
Other languages
English (en)
Icelandic (is)
Inventor
Blum Kenneth
E. Comings David
L. Ivy John
Original Assignee
Kenneth Blum, Inc.
Board Of Regents, The University Of Texas System
City Of Hope National Mecical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Blum, Inc., Board Of Regents, The University Of Texas System, City Of Hope National Mecical Center filed Critical Kenneth Blum, Inc.
Publication of IS5233A publication Critical patent/IS5233A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
IS5233A 1997-04-29 1999-10-28 Greining á fjölgenesamsætum tengdum umbunarskortsheilkenni (reward deficiency syndrome) og efnablöndum til meðferðar við því IS5233A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4439497P 1997-04-29 1997-04-29
PCT/US1998/008684 WO1998048785A2 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment

Publications (1)

Publication Number Publication Date
IS5233A true IS5233A (is) 1999-10-28

Family

ID=21932148

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5233A IS5233A (is) 1997-04-29 1999-10-28 Greining á fjölgenesamsætum tengdum umbunarskortsheilkenni (reward deficiency syndrome) og efnablöndum til meðferðar við því

Country Status (10)

Country Link
EP (1) EP0979092A2 (de)
JP (1) JP2002511850A (de)
KR (1) KR20010020422A (de)
CN (1) CN1261801A (de)
AU (1) AU7267798A (de)
CA (1) CA2288990A1 (de)
IL (1) IL132634A0 (de)
IS (1) IS5233A (de)
NO (1) NO995257L (de)
WO (1) WO1998048785A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
GB9927806D0 (en) 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
AU1810501A (en) * 2000-12-01 2002-06-11 Be Able Llc Behavior chemotherapy
ITRM20010218A1 (it) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
CN103497993A (zh) * 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
JP4942756B2 (ja) 2006-09-28 2012-05-30 三菱電機株式会社 故障検出装置、故障検出方法、および故障検出プログラム
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
AU2009259887A1 (en) * 2008-06-21 2009-12-23 B. William Downs DNA-directed customization of analgesic compounds as a therapeutic modality
WO2010005303A2 (en) * 2008-07-07 2010-01-14 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum New indicators of human longevity and biological ageing rate
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US20120022610A1 (en) * 2010-04-22 2012-01-26 Kenneth Blum Devices for Delivering Neuro Electro Adaptive Therapy NEAT
US9727691B2 (en) 2011-09-30 2017-08-08 Tokyo Metropolitan Institute Of Medical Science Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
JP2015067581A (ja) * 2013-09-30 2015-04-13 国立大学法人京都大学 多重共鳴用のプローブ
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN103990106A (zh) * 2014-06-11 2014-08-20 河北医科大学 八肽胆囊收缩素在制药中的应用
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
CN104846015B (zh) * 2015-05-27 2018-03-27 深圳先进技术研究院 特异性兴奋伏隔核中的gaba能神经元的组合物及其在改善精神分裂症异样行为中的应用
WO2017134587A1 (en) * 2016-02-02 2017-08-10 Aleva Neurotherapeutics, Sa Treatment of autoimmune diseases with deep brain stimulation
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
DE102018114364B4 (de) * 2018-06-15 2026-04-23 Susanne Koch Vorrichtungen zur Bereitstellung eines Parameters, der auf eine erhöhte Wahrscheinlichkeit des Auftretens eines postoperativen Delirs hinweist
CN109316196B (zh) * 2018-12-12 2022-07-19 上海市精神卫生中心（上海市心理咨询培训中心） 基于虚拟现实联合脑电监测的苯丙胺类兴奋剂渴求评估方法
CN110507294B (zh) * 2019-08-07 2022-02-08 北京安龙脉德医学科技有限公司 基于互联网信息传递的急救系统
CN110991044B (zh) * 2019-12-03 2023-02-24 北京机电工程研究所 基于Agent建模的飞行器系统任务可靠性评估方法
CN112862751B (zh) * 2020-12-30 2022-05-31 电子科技大学 一种用于自闭症的自动诊断装置
CN113332299A (zh) * 2021-05-27 2021-09-03 广东湛江海洋医药研究院 红景天苷在缓解糖皮质激素性骨质疏松症中的应用
KR102434668B1 (ko) * 2022-03-02 2022-08-22 주식회사 국개대표 분리 불안 증상을 개선할 수 있는 반려동물용 사료 및 그 제조방법
CN115830001B (zh) * 2022-12-22 2023-09-08 抖音视界有限公司 肠道图像处理方法、装置、存储介质及电子设备
CN116310717B (zh) * 2023-02-14 2025-06-20 长沙理工大学 目标学生网络模型训练方法及低分辨率图像识别方法
CN116820166B (zh) * 2023-06-08 2024-07-19 武汉汉联智控科技有限公司 一种高低温控温控流量系统及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US5013752A (en) * 1989-03-10 1991-05-07 Dobbins John P Prevention and treatment of alcoholism by the use of dietary chromium
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity

Also Published As

Publication number Publication date
IL132634A0 (en) 2001-03-19
EP0979092A2 (de) 2000-02-16
JP2002511850A (ja) 2002-04-16
AU7267798A (en) 1998-11-24
WO1998048785A3 (en) 1999-04-01
NO995257D0 (no) 1999-10-28
CA2288990A1 (en) 1998-11-05
NO995257L (no) 1999-12-27
WO1998048785A9 (en) 1999-05-20
CN1261801A (zh) 2000-08-02
KR20010020422A (ko) 2001-03-15
WO1998048785A2 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
NO995257D0 (no) FremgangsmÕte og materialer for diagnose og behandling av Reward Deficiency Syndrome
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
NO20000943L (no) 5-alkyl-2-arylaminofenyleddiksyrer og derivater
NO20000700D0 (no) Interleukin-18-proteiner samt fremstilling og anvendelse derav
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
DK0745396T3 (da) Blodpumpe og anvendelse deraf
DK0865778T3 (da) Hygiejniske og medicinske produkter
NO993339D0 (no) Fluidblander og tilhörende prosess
NO20001488L (no) ForhÕndsfylte ampuller og tilvirkning derav
NO983364L (no) Konsensusproteiner
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
NO20001552D0 (no) Katalysator og fremgangsmåter hvor slike benyttes
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
NO993731L (no) Pyrrolopyrazolopyrimidin-forbindelse og medisin omfattende denne
PT878467E (pt) Acidos 6-aminotetra-hidroisoquinolinacarboxilicos e 7-aminotetra-hidroisoquinolinacarboxilicos substituidos
DK1047445T3 (da) Modificerede enzymer og anvendelse heraf til peptidsyntese
NO982181D0 (no) Type IX collagen og chimerer
NO971505D0 (no) Trofinin og trofininhjelperproteiner
NO20012738D0 (no) Terapeutiske produkter og anvendelse derav
IS2065B (is) Búnaður til skömmtunar og eldunar á afurðum
EP1018551A4 (de) Megsin-protein
DE69837507D1 (de) Humanes Hedgehog-Protein
EP1012262A4 (de) Menschliches frezzeled-ähnliches protein
EP0679051A3 (de) Kontaktierung von Betätigungs- und Anzeigemitteln.